{"nctId":"NCT02143648","briefTitle":"Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus","startDateStruct":{"date":"2014-06"},"conditions":["Uremic Pruritus","Pruritus"],"count":373,"armGroups":[{"label":"nalbuphine HCl ER 60mg","type":"EXPERIMENTAL","interventionNames":["Drug: nalbuphine HCl ER tablets 60 mg BID"]},{"label":"nalbuphine HCl ER 120mg","type":"EXPERIMENTAL","interventionNames":["Drug: nalbuphine HCl ER tablets 120mg BID"]},{"label":"Sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablets BID"]}],"interventions":[{"name":"nalbuphine HCl ER tablets 60 mg BID","otherNames":["nalbuphine ER"]},{"name":"nalbuphine HCl ER tablets 120mg BID","otherNames":["nalbuphine ER"]},{"name":"Placebo tablets BID","otherNames":["sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has been receiving in-center hemodialysis for â‰¥ 3 months and are currently on a schedule of 3 times a week.\n* Subject self-categorized themselves on the Patient Assessed Disease Severity Scale during Screening\n* Subject meets standard of care hemodialysis efficiency guidelines during the three months prior to completing Screening\n* Have demonstrated pruritus intensity on the Itch NRS during screening\n* Male or female who are at least 18 years old at the time of Screening\n\nExclusion Criteria:\n\n* Subject had a significant alteration in dialysis regimen during the Screening Period\n* Subject receiving or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study.\n* Subject has pruritus that is believed to be caused by a condition unrelated to end-stage renal disease\n* Has had a history of substance abuse within 6 months prior to completing Screening\n* Subject has a known drug allergy to opioids\n* Subject is a pregnant or lactating female.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale","description":"The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.10","spread":"2.35"},{"groupId":"OG001","value":"-3.49","spread":"2.37"},{"groupId":"OG002","value":"-2.80","spread":"2.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":126},"commonTop":[]}}}